Literature DB >> 25002018

Validation of the Japanese histologic classification 2013 of immunoglobulin A nephropathy for prediction of long-term prognosis in a Japanese single-center cohort.

Ryuta Sato1,2, Kensuke Joh3, Atsushi Komatsuda4, Hiroshi Ohtani5, Shin Okuyama4, Masaru Togashi4, Ayumi Omokawa4, Mizuho Nara4, Daisuke Nagata6, Eiji Kusano6,7, Ken-Ichi Sawada4, Hideki Wakui4,8.   

Abstract

BACKGROUND: A new Japanese histologic classification (JHC) of immunoglobulin A nephropathy (IgAN) for prediction of long-term prognosis was proposed in 2013. The goal of this study was to validate the JHC system in a Japanese single-center cohort.
METHODS: A retrospective study was conducted in 198 Japanese adult patients with IgAN. Clinical findings including blood pressure, urinary protein, estimated glomerular filtration rate (eGFR), and outcomes were evaluated in these patients. The glomerular lesion percentage score (GLPS) [number of glomeruli with cellular crescents, fibrocellular crescents, global sclerosis, segmental sclerosis, or fibrous crescents/number of total obtained glomeruli × 100 (%)] was assessed in each patient and categorized into histologic grades (HGs) of HG1 (<25 %), HG2 (25-49 %), and HG3/4 (≥50 %). Associations of GLPS (HG) with disease progression (50 % eGFR decline or end-stage renal disease requiring dialysis) within 10 years after biopsy and the rate of annual eGFR decline were examined.
RESULTS: During a median follow-up period of 12.0 years after biopsy, disease progression occurred in 12.8 % (12/94) of HG1 patients, 32.3 % (21/65) of HG2 patients, and 46.2 % (18/39) of HG3/4 patients. The risk of disease progression was significantly higher in the HG2 and HG3/4 groups than in the HG1 group (odds ratios: 3.3 and 5.9 vs. 1). A higher GLPS was significantly associated with a higher risk of disease progression and a greater annual eGFR decline.
CONCLUSION: The newly proposed JHC system 2013 based on GLPS (HG) was well correlated with long-term prognosis in our cohort of Japanese adult patients with IgAN.

Entities:  

Keywords:  IgA nephropathy; Japanese histologic classification; Long-term prognosis

Mesh:

Year:  2014        PMID: 25002018     DOI: 10.1007/s10157-014-1004-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  22 in total

1.  Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.

Authors:  O Hotta; M Miyazaki; T Furuta; S Tomioka; S Chiba; I Horigome; K Abe; Y Taguma
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

2.  Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system.

Authors:  Hyun Soon Lee; Myung Suk Lee; Sa Min Lee; Sang Yun Lee; Eun Sun Lee; Eun Young Lee; So Yeon Park; Jin Suk Han; Sungkwon Kim; Jung Sang Lee
Journal:  Nephrol Dial Transplant       Date:  2004-12-23       Impact factor: 5.992

Review 3.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

4.  Corticosteroids in IgA nephropathy: a randomised controlled trial.

Authors:  C Pozzi; P G Bolasco; G B Fogazzi; S Andrulli; P Altieri; C Ponticelli; F Locatelli
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

5.  Primary IgA glomerulonephritis and Schönlein-Henoch purpura nephritis: Clinicopathological and immunohistological characteristics.

Authors:  Y Nakamoto; Y Asano; K Dohi; M Fujioka; H Iida; H Kida; Y Kibe; N Hattori; J Takeuchi
Journal:  Q J Med       Date:  1978-10

6.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

7.  The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.

Authors:  Daniel C Cattran; Rosanna Coppo; H Terence Cook; John Feehally; Ian S D Roberts; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Chi Bon Leung; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

8.  IgA nephropathy: morphologic predictors of progressive renal disease.

Authors:  S M Lee; V M Rao; W A Franklin; M S Schiffer; A J Aronson; B H Spargo; A I Katz
Journal:  Hum Pathol       Date:  1982-04       Impact factor: 3.466

9.  Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

Authors:  Claudio Pozzi; Simeone Andrulli; Lucia Del Vecchio; Patrizia Melis; Giovanni B Fogazzi; Paolo Altieri; Claudio Ponticelli; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more
  4 in total

1.  The Japanese Histologic Classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients.

Authors:  Ahmad Baseer Kaihan; Yoshinari Yasuda; Takayuki Katsuno; Sawako Kato; Takahiro Imaizumi; Takaya Ozeki; Manabu Hishida; Takanobu Nagata; Masahiko Ando; Naotake Tsuboi; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2017-03-27       Impact factor: 2.801

2.  Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Schönlein purpura nephritis: a multicenter retrospective cohort study.

Authors:  Koji Inagaki; Ahmad Baseer Kaihan; Asaka Hachiya; Takaya Ozeki; Masahiko Ando; Sawako Kato; Yoshinari Yasuda; Shoichi Maruyama
Journal:  BMC Nephrol       Date:  2018-08-17       Impact factor: 2.388

3.  Ambulatory blood pressure and tubulointerstitial injury in patients with IgA nephropathy.

Authors:  Kotaro Haruhara; Nobuo Tsuboi; Kentaro Koike; Go Kanzaki; Yusuke Okabayashi; Yoichi Miyazaki; Tetsuya Kawamura; Makoto Ogura; Takashi Yokoo
Journal:  Clin Kidney J       Date:  2015-09-03

Review 4.  A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity.

Authors:  Hideo Okonogi; Tetsuya Kawamura; Kensuke Joh; Kentaro Koike; Yoichi Miyazaki; Makoto Ogura; Nobuo Tsuboi; Keita Hirano; Masato Matsushima; Takashi Yokoo; Satoshi Horikoshi; Yusuke Suzuki; Takashi Yasuda; Sayuri Shirai; Takanori Shibata; Motoshi Hattori; Yuko Akioka; Ritsuko Katafuchi; Akinori Hashiguchi; Satoshi Hisano; Akira Shimizu; Kenjiro Kimura; Shoichi Maruyama; Seiichi Matsuo; Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2018-10-26       Impact factor: 2.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.